BioCryst Pharmaceuticals Inc (BCRX) Stock Price

BCRXStock

$7.79+15.92%52W

Market Cap$1.99B

P/E7.54x

PEG Ratio9.39

Div yield—

Beta0.55

BCRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-29.35%

Price vs S&P 500 (4W)-9.75%

PEG Ratio9.39

VGM Score70.79

P/E Ratio (Annual)7.54x

P/CF (Annual)5.73x

Book Value / Share (Quarterly)$0.19

P/TBV (Annual)15.62x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)47.83%

Cash Flow / Share (Quarterly)$1.52

Price vs S&P 500 (YTD)-12.05%

Gross Margin (TTM)97.78%

Net Profit Margin (TTM)-40.90%

EPS (TTM)$-1.50

10-Day Avg Trading Volume4.23M

EPS Excl Extra (TTM)$-1.50

Revenue Growth (5Y)117.92%

EPS (Annual)$1.21

ROI (Annual)-92.13%

Gross Margin (Annual)97.82%

Net Profit Margin (5Y Avg)-53.26%

Cash / Share (Quarterly)$1.38

P/E Basic Excl Extra (TTM)8.33x

Revenue Growth QoQ (YoY)33.61%

P/E Normalized (Annual)7.54x

ROA (Last FY)51.32%

Revenue Growth TTM (YoY)68.72%

EBITD / Share (TTM)$-1.37

ROE (5Y Avg)-820.53%

Operating Margin (TTM)-34.69%

Cash Flow / Share (Annual)$1.62

P/B Ratio59.24x

P/B Ratio (Quarterly)18.05x

Net Income / Employee (Annual)$606,600

EV / Revenue (TTM)2.83x

Net Interest Coverage (TTM)4.91x

ROA (TTM)-77.58%

EPS Growth QoQ (YoY)1179.65%

EV / EBITDA (TTM)8.18x

EPS Incl Extra (Annual)$1.21

Current Ratio (Annual)2.06x

Quick Ratio (Quarterly)2.22x

3-Month Avg Trading Volume4.66M

52-Week Price Return15.92%

EV / Free Cash Flow (Annual)7.71x

P/E Incl Extra (TTM)8.33x

Revenue / Employee (TTM)$2,162,300

Tangible BV / Share (Quarterly)$1.73

P/S Ratio (Annual)2.28x

Asset Turnover (Annual)1.70x

52-Week High$11.22

Operating Margin (5Y Avg)-27.19%

EPS Excl Extra (Annual)$1.21

CapEx CAGR (5Y)37.07%

Tangible BV CAGR (5Y)-18.04%

26-Week Price Return-19.44%

Quick Ratio (Annual)1.95x

13-Week Price Return-16.15%

Total Debt / Equity (Annual)2.09x

Current Ratio (Quarterly)2.32x

Enterprise Value$2.66B

Revenue / Share Growth (5Y)106.57%

Asset Turnover (TTM)1.90x

Book Value / Share Growth (5Y)-25.06%

Revenue / Employee (Annual)$2,011,100

Inventory Turnover (Annual)2.83x

Pretax Margin (Annual)30.56%

Cash / Share (Annual)$1.29

3-Month Return Std Dev43.81%

Gross Margin (5Y Avg)97.31%

Net Income / Employee (TTM)$-884,300

ROE (Last FY)-284.33%

Net Interest Coverage (Annual)-4.80x

EPS Basic Excl Extra (Annual)$1.21

P/FCF (TTM)4.42x

Receivables Turnover (TTM)9.32x

EV / Free Cash Flow (TTM)6.85x

Total Debt / Equity (Quarterly)2.26x

EPS Incl Extra (TTM)$-1.50

Receivables Turnover (Annual)9.41x

ROI (TTM)-106.66%

P/S Ratio (TTM)2.12x

Pretax Margin (5Y Avg)-52.58%

Revenue / Share (Annual)$4.00

Tangible BV / Share (Annual)$0.72

Forward P/E23.66x

Price vs S&P 500 (52W)0.39%

P/E Ratio (TTM)8.33x

Year-to-Date Return-0.13%

5-Day Price Return-6.82%

EPS Normalized (Annual)$1.21

ROA (5Y Avg)-17.37%

Net Profit Margin (Annual)30.16%

Month-to-Date Return-6.48%

Cash Flow / Share (TTM)$-1.24

EBITD / Share (Annual)$1.49

Operating Margin (Annual)37.00%

LT Debt / Equity (Annual)1.08x

P/CF (TTM)5.09x

ROI (5Y Avg)-77.15%

P/E Excl Extra (TTM)8.33x

LT Debt / Equity (Quarterly)0.80x

EPS Basic Excl Extra (TTM)$-1.50

P/TBV (Quarterly)4.30x

P/B Ratio (Annual)13.88x

Inventory Turnover (TTM)3.18x

Pretax Margin (TTM)-40.53%

Book Value / Share (Annual)$0.25

Price vs S&P 500 (13W)-18.83%

Beta0.55x

P/FCF (Annual)5.77x

Revenue / Share (TTM)$3.55

ROE (TTM)-328.82%

52-Week Low$6.23

vGradeB

gGradeA

mGradeB

vgmGradeB

BCRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.23	$0.35	+49.40%(+$0.12)
Q1 2026	May 6, 2026	$0.11	$0.14	+27.68%(+$0.03)
Q4 2025	Feb 26, 2026	$0.07	$0.21	+197.57%(+$0.14)
Q3 2025	Nov 3, 2025	$0.07	$0.16	+125.29%(+$0.09)
Q2 2025	Aug 4, 2025	$0.03	$0.04	+47.12%(+$0.01)

BCRX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

4.18

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals is a biotechnology company developing small-molecule drugs that target key enzymes involved in infectious and inflammatory diseases. The company's clinical and preclinical pipeline addresses acute and seasonal influenza, hereditary angioedema, filoviruses including Ebola and Marburg, and oncology. BioCryst leverages computational biology and medicinal chemistry to advance its targeted therapeutic candidates.